Medicare To Modify Its Claims Monitoring Policy For Use Of Esas For Anemia Treatment In Dialysis

The Centers for Medicare & Medicaid Services (CMS) announced it is strengthening its erythropoiesis stimulating agent (ESA) Monitoring Policy (EMP) for claims for ESAs used to treat anemia in Medicare beneficiaries who are receiving dialysis treatment for end stage renal disease...